Results 251 to 260 of about 390,088 (309)

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing. [PDF]

Adv Ther
Kodjikian L, Arias Barquet L, Papp A, Kertes PJ, Midena E, Ernest J, Silva R, Schmelter T, Niesen T, Leal S.   +9 more
europepmc   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE). [PDF]

Eye (Lond)
Wijesingha N, Kotecha A, Margaron P, Sivaprasad S.   +3 more
europepmc   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Switching to Intravitreal Brolucizumab after Ranibizumab or Aflibercept Using Treat and Extend Regimen for Neovascular Age-Related Macular Degeneration in Japanese Patients: 1-Year Results and Factors Associated with Treatment Responsiveness. [PDF]

J Clin Med
Hirayama K, Yamamoto M, Honda S, Kyo A, Misawa N, Kohno T.   +5 more
europepmc   +1 more source

Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial.

JAMA Ophthalmol
Maguire MJ, Laidlaw A, Hammond C, Muqit MMK, Steel D, Dinah C, Lee E, Hillier R, Almeida G, Hussain R, Gordon-Bennet P, Hughes E, Alexander P, Vaideanu-Collins D, Jackson T.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Treat and extend regimen for diabetic macular oedema—a systematic review and meta-analysis

Graefe's Archive for Clinical and Experimental Ophthalmology, 2022
Various treatment regimens are currently practiced in the treatment of CI-DMO (centre-involving diabetic macular oedema). In recent years, there has been a growing body of evidence supporting a treat and extend (T&E) regimen for DMO which offers the promise of comparable visual and anatomical outcomes while reducing injection burden. This meta-analysis
Sheng Y. Lim, W. Wong, Ivan Seah, H. W. Chan, Xinyi Su, G. Lingam, Y. Yuen   +6 more
semanticscholar   +3 more sources

Treat-And-Extend Regimens with Anti-Vegf Agents in Retinal Diseases [PDF]

Retina, 2015
PURPOSE: A review of treat-and-extend regimens (TERs) with intravitreal anti-vascular endothelial growth factor agents in retinal diseases. METHODS: There is a lack of consensus on the definition and optimal application of TER in clinical practice. This article describes the supporting evidence and subsequent development of a generic algorithm for TER ...
Freund, K. Bailey, Korobelnik, Jean François, Devenyi, Robert, Framme, Carsten, Galic, John, Herbert, Edward, Hoerauf, Hans, LANZETTA, Paolo, Michels, Stephan, Mitchell, Paul, Monés, Jordi, Regillo, Carl, Tadayoni, Ramin, Talks, James, Wolf, Sebastian   +14 more
core   +7 more sources

One year outcomes of treat and extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy

European Journal of Ophthalmology, 2021
Purpose: To compare the 1-year outcomes of treat-and-extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy (PCV), by the means of visual acuity (VA), frequency of recurrence of polypoidal lesions and ...
Maria Theodorou, Panagiotis Theodossiadis, Nikolaos Gouliopoulos   +2 more
exaly   +2 more sources

Deep learning models for human age prediction to prevent, treat and extend life expectancy: DCPV taxonomy

Multimedia tools and applications, 2023
The implementation of Deep Learning (DL) Prediction techniques for Human Age Prediction (HAP) has been widely researched and studied to prevent, treat, and extend life expectancy.
Abeer Alsadoon, Ghazi Al-Naymat, Md Rafiqul Islam   +2 more
semanticscholar   +2 more sources